Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival
Margret Merino, Yvette L. Kasamon, Marc R. Theoret, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 15, pp. 2706-2712
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
Manish A. Shah, Kohei Shitara, Jaffer A. Ajani, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 2133-2141
Open Access | Times Cited: 243
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
Xu Liu, Yuan Zhang, Kun-Yu Yang, et al.
The Lancet (2024) Vol. 403, Iss. 10445, pp. 2720-2731
Closed Access | Times Cited: 50
Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval
Ian T. T. Liu, Aaron S. Kesselheim, Edward R. Scheffer Cliff
JAMA (2024) Vol. 331, Iss. 17, pp. 1471-1471
Closed Access | Times Cited: 40
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
Thomas Yau, Ahmed O. Kaseb, Ann‐Lii Cheng, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 4, pp. 310-322
Closed Access | Times Cited: 32
Nanomedomics
Ganghao Liang, Wanqing Cao, Dongsheng Tang, et al.
ACS Nano (2024) Vol. 18, Iss. 17, pp. 10979-11024
Closed Access | Times Cited: 31
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
Benjamin Besse, Enriqueta Felip, Rosario García Campelo, et al.
Annals of Oncology (2023) Vol. 34, Iss. 10, pp. 920-933
Open Access | Times Cited: 29
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed
Anushka Walia, Jordan Tuia, Vinay Prasad
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 885-895
Open Access | Times Cited: 28
Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development
Wei Gao, Jiang Liu, Blerta Shtylla, et al.
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 13, Iss. 5, pp. 691-709
Open Access | Times Cited: 23
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis
Bernardo H. L. Goulart, Sirisha L. Mushti, Somak Chatterjee, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 4, pp. 455-462
Closed Access | Times Cited: 13
Development of a Joint Tumor Size–Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision‐Making
Herbert Struemper, Chetan Rathi, Morris Muliaditan, et al.
CPT Pharmacometrics & Systems Pharmacology (2025)
Open Access | Times Cited: 1
Correlation Between Progression-Free and Overall Survival in Patients with Hodgkin Lymphoma: A Comprehensive Analysis of Individual Patient Data from Randomized GHSG Trials
Paul J. Bröckelmann, Horst Müller, Michael Fuchs, et al.
Annals of Oncology (2024)
Open Access | Times Cited: 6
Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma
Bruno Paiva, Anastasiia Zherniakova, Jorge M. Núñez‐Córdoba, et al.
Blood Advances (2023) Vol. 8, Iss. 1, pp. 219-223
Open Access | Times Cited: 12
Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients
Giulia Pasello, Aline S.C. Fabricio, Paola Del Bianco, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Endpoint Surrogacy in First-Line Chronic Lymphocytic Leukemia
Florian Simon, Rudy Ligtvoet, Sandra Robrecht, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 4
Using Win Odds to Improve Commit‐to‐Phase‐3 Decision‐Making in Oncology
Benjamin Hartley, Thomas Drury, Brian Di Pace, et al.
Statistics in Medicine (2025) Vol. 44, Iss. 5
Open Access
Success and Futility Criteria for Accelerated Approval of Oncology Drugs
Dong Xi, Jiangtao Gou
Pharmaceutical Statistics (2025) Vol. 24, Iss. 2
Closed Access
PD-1 transcriptomic landscape across cancers and implications for immune checkpoint blockade outcome
Hui‐Zi Chen, Na Hyun Kim, Daisuke Nishizaki, et al.
npj Genomic Medicine (2025) Vol. 10, Iss. 1
Open Access
Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials
Paul J. Bröckelmann, Horst Müller, Martin Fuchs, et al.
Leukemia (2025)
Open Access
Efficacy and safety of PD-1/PD-L1 inhibitors combined with tyrosine kinase inhibitors as first-line treatment for hepatocellular carcinoma: a meta-analysis and trial sequential analysis of randomized controlled trials
Peng Tang, Fei Zhou
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Assessment of Objective Response Rate by Investigator vs. Blinded Independent Central Review in Pivotal Trials of Oncology Drugs for Solid Tumor Indications
Marjorie E. Zettler
Cancers (2025) Vol. 17, Iss. 7, pp. 1096-1096
Open Access
Progression-free survival: a true endpoint in first-line treatment for classic Hodgkin Lymphoma?
Naoto Yamauchi, Dai Maruyama
Annals of Oncology (2025) Vol. 36, Iss. 4, pp. 356-358
Closed Access
Comparison of mTOR inhibitors combined with endocrine therapy versus that alone in breast cancer: a meta-analysis
Wei Zhang, Xinru Jia, Dandi Lou, et al.
Future Oncology (2025), pp. 1-11
Closed Access
Association between MRI-measured bone marrow cellularity and clinical outcomes among cervical cancer patients treated with PD-1 inhibitors
Jie Lou, Yi Li, Ruijie Li, et al.
International Journal of Gynecological Cancer (2025), pp. 101808-101808
Closed Access
Adjuvant immunotherapy improves survival in completely resected stage IB–III NSCLC: a systematic review and meta-analysis
Hong Huang, Pengchen Bao, Hongyu Jin, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Role of Overall Survival in Cancer Treatment Approval: Comment on “Monitoring Overall Survival in Pivotal Trials in Indolent Cancers”
Boris Freidlin, Edward L. Korn
Statistics in Biopharmaceutical Research (2025) Vol. 17, Iss. 2, pp. 175-178
Closed Access
Page 1 - Next Page

Scroll to top